Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 120HER2-positive Breast Cancer 10Stomach Neoplasms 9Neoplasm Metastasis 6Neoplasms 4Inflammatory Breast Neoplasms 4Esophageal Neoplasms 3Adenocarcinoma Of Esophagus 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Invasive Breast Cancer 2HER2-positive Metastatic Breast Cancer 2HER2-positive Early Breast Cancer 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Solid Tumors 1Resectable HER2-positive Breast Cancer 1Patient Preference 1Pathologic Complete Response 1Osteitis Deformans 1Metastatic HER2-positive Breast Cancer 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Gastric Cancer 1HER2-positive Carcinoma of Breast 1HER2-positive Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Early or Locally Advanced Breast Cancer 1HER2 Positive Early Breast Cancer 1Endometrial Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

Letrozole 5Paclitaxel 4atamestane 3Toremifene 3Tamoxifen 3Cyclophosphamide 3Estrogen Receptor Modulators 2Epirubicin 2Doxorubicin 2Docetaxel 2Carboplatin 2Capecitabine 2Aromatase Inhibitors 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2pertuzumab 1ferric carboxymaltose 1atezolizumab 1Vinorelbine 1Trastuzumab 1TP protocol 1Surgical Procedures, Operative 1Radiotherapy 1Medroxyprogesterone 1Fulvestrant 1Fluorouracil 1Estrogens, Conjugated (USP) 1Cisplatin 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Ductal, Breast × Trastuzumab × Clear all
NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡